168 related articles for article (PubMed ID: 24730479)
1. Is there an ethical obligation to disclose controversial risk? A question from the ACCORD Trial.
DeMarco JP; Ford PJ; Patton DJ; Stewart DO
Am J Bioeth; 2014; 14(4):4-10. PubMed ID: 24730479
[TBL] [Abstract][Full Text] [Related]
2. Response to the open peer commentaries on "Is there an ethical obligation to disclose controversial risk? A question from the ACCORD Trial".
DeMarco JP; Ford PJ; Patton DJ; Stewart DO
Am J Bioeth; 2014; 14(4):W1-2. PubMed ID: 24730505
[No Abstract] [Full Text] [Related]
3. Disclosing controversial risk in informed consent: how serious is serious?
Kocarnik JM
Am J Bioeth; 2014; 14(4):13-4. PubMed ID: 24730481
[No Abstract] [Full Text] [Related]
4. Equipoise and nonmedical risks.
Boesch B
Am J Bioeth; 2014; 14(4):16-8. PubMed ID: 24730483
[No Abstract] [Full Text] [Related]
5. The ethical imperative of risk disclosure in research: the answer is always yes.
Quinn GP; Haura EB; Murphy D
Am J Bioeth; 2014; 14(4):18-9. PubMed ID: 24730484
[No Abstract] [Full Text] [Related]
6. Disclosure of risks and uncertainties are especially vital in light of regenerative medicine.
Niemansburg SL; Habets MG; van Delden JJ; Bredenoord AL
Am J Bioeth; 2014; 14(4):14-6. PubMed ID: 24730482
[No Abstract] [Full Text] [Related]
7. Challenging the requirements for disclosing risk to clinical research participants.
Markman M
Am J Bioeth; 2014; 14(4):11-2. PubMed ID: 24730480
[No Abstract] [Full Text] [Related]
8. Researchers have an ethical obligation to disclose the availability of off-label marketed drugs.
Silber TJ
Am J Bioeth; 2014; 14(4):52. PubMed ID: 24730497
[No Abstract] [Full Text] [Related]
9. The ethics of disclosing to research subjects the availability of off-label marketed drugs.
Taylor HA; Kuwana E; Wilfond BS
Am J Bioeth; 2014; 14(4):51. PubMed ID: 24730496
[No Abstract] [Full Text] [Related]
10. Which alternatives should investigators disclose to research subjects?
Phillips J; Wendler D
Am J Bioeth; 2014; 14(4):54-5. PubMed ID: 24730499
[No Abstract] [Full Text] [Related]
11. Disclosing clinical trial results: publicity, significance and independence.
Liao SM; Sheehan M; Clarke S
Am J Bioeth; 2009 Aug; 9(8):W3-5. PubMed ID: 19998144
[No Abstract] [Full Text] [Related]
12. Disclosure of adverse clinical trial results--should legal immunity be granted to drug companies?
Vernillo A
Am J Bioeth; 2009 Aug; 9(8):45-7. PubMed ID: 19998162
[No Abstract] [Full Text] [Related]
13. The duty to disclose (even more) adverse clinical trial results.
Hassoun N
Am J Bioeth; 2009 Aug; 9(8):33-4. PubMed ID: 19998155
[No Abstract] [Full Text] [Related]
14. Respecting participant autonomy and the disclosure of clinical trial results.
Oakley J
Am J Bioeth; 2009 Aug; 9(8):38. PubMed ID: 19998158
[No Abstract] [Full Text] [Related]
15. Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results.
Banja JD; Dunlop B
Am J Bioeth; 2009 Aug; 9(8):39-41. PubMed ID: 19998159
[No Abstract] [Full Text] [Related]
16. The relevance of research study phase to disclosure of off-label drug availability.
Baskaran A; Sade RM
Am J Bioeth; 2014; 14(4):53-4. PubMed ID: 24730498
[No Abstract] [Full Text] [Related]
17. The duty to disclose adverse clinical trial results.
Liao SM; Sheehan M; Clarke S
Am J Bioeth; 2009 Aug; 9(8):24-32. PubMed ID: 19998154
[TBL] [Abstract][Full Text] [Related]
18. Compounding risks to patients: selective disclosure is not an option.
McGoey L
Am J Bioeth; 2009 Aug; 9(8):35-6. PubMed ID: 19998156
[No Abstract] [Full Text] [Related]
19. Consent and the ethical duty to participate in health data research.
Ballantyne A; Schaefer GO
J Med Ethics; 2018 Jun; 44(6):392-396. PubMed ID: 29358219
[TBL] [Abstract][Full Text] [Related]
20. Improving subject recruitment by maintaining truly informed consent: a practical benefit of disclosing adverse clinical trial results.
Shah KR; Batzer FR
Am J Bioeth; 2009 Aug; 9(8):36-7. PubMed ID: 19998157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
